16.10
-0.43 (-2.60%)
Previous Close | 16.53 |
Open | 16.51 |
Volume | 101,879 |
Avg. Volume (3M) | 219,293 |
Market Cap | 1,011,872,128 |
Price / Sales | 60.23 |
Price / Book | 35.77 |
52 Weeks Range | |
Earnings Date | 11 Nov 2024 - 15 Nov 2024 |
Diluted EPS (TTM) | -0.790 |
Total Debt/Equity (MRQ) | 32.05% |
Current Ratio (MRQ) | 4.57 |
Operating Cash Flow (TTM) | -35.44 M |
Levered Free Cash Flow (TTM) | -19.12 M |
Return on Assets (TTM) | -50.06% |
Return on Equity (TTM) | -100.65% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
Medical Instruments & Supplies (Global) | Mixed | Mixed | |
Stock | Pulse Biosciences, Inc | Mixed | Mixed |
Stockmoo Score
Analyst Consensus | NA |
Insider Activity | NA |
Price Volatility | -1.5 |
Technical Moving Averages | 1.5 |
Technical Oscillators | -0.5 |
Average | -0.17 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems. |
|
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
Investment Style | Small Value |
% Held by Insiders | 72.20% |
% Held by Institutions | 7.99% |
Ownership
Name | Date | Shares Held |
---|---|---|
Griffin Asset Management, Inc. | 30 Jun 2024 | 257,679 |
Westside Investment Management, Inc. | 30 Jun 2024 | 63,600 |
Spotlight Asset Group, Inc. | 30 Jun 2024 | 40,290 |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
12 Aug 2024 | Announcement | Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results |
12 Aug 2024 | Announcement | Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors |
08 Aug 2024 | Announcement | Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System |
01 Aug 2024 | Announcement | Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences |
29 Jul 2024 | Announcement | Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |